XCancer

SENtinel Lymph Node Mapping With GAllium-68-tilmanocept PET/CT in High/High-intermediate Risk Endometrial Cancer: a Pilot Study

Description:

This pilot study evaluates the feasibility of 68Ga-tilmanocept PET/CT for SLN mapping in patients with endometrial cancer.

Sponsor:

UMC Utrecht

Phase:

Phase 3

Contacts:

Ilse GT Baeten, MD

i.g.t.baeten@umcutrecht.nl

+31887553068

Cornelis G Gerestein, MD, PhD

c.g.gerestein-2@umcutrecht.nl

+31616770541

Government Study Link:

NCT05446324 - Click here to see study on

ClinicalTrials.gov

Isotope(s):
Target(s):